{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216758","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2026-05-11T20:08:24+00:00","discovered_at":"2026-05-11T20:10:00.393739+00:00","generated_at":"2026-05-11T22:31:49.381959+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026","bullets":["Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).","Cash & securities $101.1M; pro forma $128.9M including Mayo $25M equity and ATM activity.","Mayo collaboration to accelerate SC451; Mayo made $25M equity investment with option for another $25M.","SC451 Phase 1 IND filing expected later this year; SG293 clinical data presented May 12 at ASGCT.","SG227 (BCMA CAR) expected to begin clinical testing as early as mid-2027, contingent on SG293 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216758","json":"https://secwatch.observer/filing/0001193125-26-216758.json","markdown":"https://secwatch.observer/filing/0001193125-26-216758.md","text":"https://secwatch.observer/filing/0001193125-26-216758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/0001193125-26-216758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/sana-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:31:49.381959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28f88be6149c1befc1a8274cedfd5e54adced11f","claim":"Sana Biotechnology, Inc. reported financial results for first quarter 2026.","evidence_excerpt":"On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/0001193125-26-216758-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}